Pseudomonas Aeruginosa Infections Among COVID-19 Patients in Intensive Care Units at CHRU of Nancy (Pyo-COVID-3)

COVID-19 Clinical Trial

— Pyo-COVID-3  

Official title:

Pseudomonas Aeruginosa Infections Among COVID-19 Patients in Intensive Care Units at Nancy University Hospital During the First Three Epidemic Waves: a Retrospective Study (Pyo-COVID-3)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06141837
• Other study ID #: 2023PI186
• Status: Completed
• Start date: December 1, 2023
• Est. completion date: April 20, 2024

Study information

• Verified date: May 2024
• Source: Central Hospital, Nancy, France
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

P. aeruginosa is an opportunistic bacterium known to be responsible for numerous healthcare-associated infections, particularly in intensive care units (ICU). The frequency of these infections seems to have increased during the first waves of the COVID-19 pandemic. Identifying cases of co-infection and secondary infections with P. aeruginosa in patients with COVID-19 would provide a better understanding of the epidemiological evolution and characteristics of infected patients. Treatment of P. aeruginosa infections requires the use of antibiotics. Antibiotic resistance is a growing problem, with an increase in resistance among P. aeruginosa strains. The misuse of antibiotics to treat patients can accentuate the phenomenon of antibiotic resistance, and failure to take account of resistance revealed by antibiograms can compromise patient recovery. Analysis of bacteriological results and patient medical records would enable a posteriori evaluation of the proper use of antibiotics (choice and adaptation of molecules, doses and duration of prescriptions), and identify any areas for improvement. The main objective is to describe the evolution of P. aeruginosa infections in ICU patients with COVID-19 during the first 3 waves of COVID-19 (01/03/2020 to 31/05/2021). Secondary objectives are to describe the typology of P. aeruginosa strains identified among included patients (sampling sites and resistance profiles), to assess antibiotic prescriptions for these patients and to describe the relapse rate of included patients with a first P. aeruginosa infection.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 51
• Est. completion date: April 20, 2024
• Est. primary completion date: March 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult patients hospitalized for at least 48 h in an intensive care unit (ICU) at CHRU-Nancy for acute respiratory distress syndrome due to COVID-19.
• Patients hospitalized from 1st March 2020 to 31st May 2021.
• Patient developed an hospital-acquired infection caused by P. aeruginosa during their ICU stay.

Exclusion Criteria:

• Patients <18 years old.
• Patient without COVID-19 at the ICU admission.
• Patients with P. aeruginosa isolated <48 hours following ICU admission.
• Patients who did not want to be included in the study.

Related Conditions & MeSH terms

• COVID-19
• Infections
• Pseudomonas Aeruginosa
• Pseudomonas Infections

Intervention

Other:
• Observation
No intervention: observational study

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Central Hospital, Nancy, France

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	P. aeruginosa occurence	The occurrence of Pseudomonas aeruginosa infection during the ICU stay of a COVID-19 patient.	From 01 March 2020 to 31 May 2021.
Secondary	P. aeruginosa sample	Distribution of different types of samples (respiratory, blood, urine, etc.) positive for P. aeruginosa.	From 01 March 2020 to 31 May 2021.
Secondary	P. aeruginosa resistance	The proportion of resistance to the various antibiotics tested on the P. aeruginosa strains identified.	From 01 March 2020 to 31 May 2021.
Secondary	P. aeruginosa antibiotic treatment	Compliance of antibiotic prescriptions with reference recommendations is assessed by comparing data from patients' medical records.	From 01 March 2020 to 31 May 2021.
Secondary	P. aeruginosa recurrence	Occurrence of a new P. aeruginosa infection.	From 01 March 2020 to 31 May 2021.

External Links

•   Article